Screener
Tango Therapeutics TNGX TNG456Direct Program Expenses-RD — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Oncology Segment / Three Months Ended March 31, 2026 | Oncology Segment / Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | — | $5,392 |
| Less: | ||
| vopimetostat direct program expenses - R&D | 9,332 | 5,461 |
| TNG456 direct program expenses - R&D | 2,063 | 1,324 |
| TNG260 direct program expenses - R&D | 2,009 | 1,730 |
| TNG961 direct program expenses - R&D | 408 | 2,221 |
| TNG908 direct program expenses* - R&D | 581 | 1,712 |
| Discovery direct program expenses - R&D | 1,872 | 4,679 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's tng456direct program expenses-rd — research and development expense?
- Tango Therapeutics (TNGX) reported tng456direct program expenses-rd — research and development expense of $2.06M in Q1 2026.
- How has Tango Therapeutics's tng456direct program expenses-rd — research and development expense changed year-over-year?
- Tango Therapeutics's tng456direct program expenses-rd — research and development expense increased by 55.8% year-over-year, from $1.32M to $2.06M.
- What does tng456direct program expenses-rd — research and development expense mean?
- This metric represents the direct research and development costs specifically allocated to the TNG456 clinical or preclinical program. It captures the internal and external expenditures required to advance this specific oncology asset through its development lifecycle, including laboratory testing, clinical trial execution, and regulatory preparation. Tracking this expense allows investors to assess the capital intensity and investment priority of this particular drug candidate within the company's broader precision medicine pipeline.
Ask your AI about Tango Therapeutics's tng456direct program expenses-rd — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude